Reyon Pharmaceutical Cuts Conversion Price to KRW 10,170 From KRW 11,858
Reyon Pharmaceutical cut its third-series convertible bond conversion price to KRW 10,170 from KRW 11,858, effective Oct. 16, 2026. The adjustment increases shares convertible from KRW 85 billion of outstanding bonds to 8,357,915 from 7,168,156. The reduction reflects issuance of fourth-series convertible bonds with a